Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29811792 | 0.82 | CA12 (0.42) | GPR119GPBAR1NAMPT | |
| SCHEMBL23144008 | 0.82 | CA12 (0.42) | GPR119GPBAR1NAMPT | |
| SCHEMBL29450028 | 0.81 | GPR119 (0.40) | GPR119GPBAR1 | |
| SCHEMBL27888384 | 0.80 | GSK3B (0.40) | TDP1SIRT3GPBAR1TACR1 | |
| SCHEMBL838521 | 0.80 | RAB9A (0.39) | TDP1SIRT3HSD17B1RAB9ASTS | |
| SCHEMBL31751282 | 0.80 | RAB9A (0.35) | RAB9AGPR119NAMPTUSP30CYP17A1 | |
| SCHEMBL9571667 | 0.76 | RAB9A (0.45) | TDP1RAB9AGPR119NAMPTALDH1A1 | |
| SCHEMBL22885615 | 0.74 | SSTR4 (0.33) | USP30 | |
| SCHEMBL16587791 | 0.74 | PIM2 (0.38) | GPR119 | |
| SCHEMBL12097393 | 0.73 | PAX8 (0.36) | RAB9AGPBAR1TACR1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267349-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-08-25 | — | — | US | disclosed |
| EP-4034239-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| CN-114401969-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20210107921-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| WO-2021058416-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107921-A1 | HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1, CCNY | TDP1 2774/4885SIRT3 571/4885HSD17B1 4045/4885 |
| US-20220267349-A1 | HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1, CCNY | TDP1 2774/4885SIRT3 571/4885HSD17B1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.